TSX closed
Loading markets…
Stocks

Why Apotex Health Corp stock is skyrocketing today

By Wealth Awesome -

This move is archived. Current quotes and coverage live on the stock page.

Stocks & ETFs:APTX.TO

Follow APTX

Photos provided by Pexels

Apotex Health Corp's stock surged by over 5% in the last trading session, marking a significant milestone in its market journey.

In a noteworthy performance on the Toronto Stock Exchange, Apotex Health Corp (APTX.TO) saw its stock price increase by 5.26%, closing at CA$36.44. This upward momentum reflects growing investor confidence in the company's recent strategic moves and market positioning.

Apotex Health Corp

APTX.TO

Full stock page →

APTX.TO

Apotex Health Corp

Source:WealthAwesomeWealthAwesome
↑ $6.74 (25.02%)
103 day period
$26.96$33.28$39.61Jun 10Aug 24Nov 5

Market cap

$7.75B

52W high

$40.11

52W low

$26.01

1W change

+3.32%

Analyst Price Targets

Based on analyst covering APTX · as of Sep 23, 2026

📈

Wall Street analysts forecast APTX stock price to rise 22.8% over the next 12 months.

Consensus

Bullish

Based on avg. target vs last close (formal rating unavailable for Canadian listings)

Avg. Target

C$41.37

+22.8% Upside

Previously C$41.23 on Sep 17, 2026

Current Price

C$33.70

Last close

Compare analyst targets →

Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.

Wealth Awesome Price Forecast

WA Model

Statistical 90-day price range based on APTX's historical volatility

HistoricalForecast68%95%
C$20.05C$24.60C$29.15C$33.70C$38.25C$42.80TodayJun 29Sep 2Nov 5Dec 18Jan 31Mar 15

30-Day Vol

29.2%

Annualized

90-Day Vol

41.8%

Annualized

Trend (90d)

-39.1%

Annualized drift

90d Mean

C$29.31

Expected price

HorizonExpected68% Range (1σ)
30 trading daysC$32.17C$29.08 – C$35.58
60 trading daysC$30.70C$26.62 – C$35.41
90 trading daysC$29.31C$24.61 – C$34.90

Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.

Investor takeaway: For Canadian investors, Apotex Health Corp's recent gains highlight the potential of biotech firms in the current market, especially those making strides in product approvals and strategic partnerships.

Apotex Health Corp's stock rises 5.26% in one day

With a market cap of CA$7.87 billion, Apotex is now a significant player in the Canadian biotech landscape, reflecting its growing influence and investor interest.

Bull case

The recent approval of SEVMIA™, a generic semaglutide for chronic weight management, puts Apotex Health Corp in a strong position within the expanding health sector. This product could tap into a lucrative market, driving revenue growth and boosting investor sentiment.

Bear case

Despite today's gains, the biotech sector can be unpredictable. Any setbacks in product launches or regulatory hurdles could affect Apotex's stock performance. Investors should stay cautious and keep an eye on upcoming developments closely.

Market Performance Overview

In the latest trading session, Apotex Health Corp's stock closed at CA$36.44, reflecting a 5.26% increase. This surge is indicative of a positive market reception following the company's strategic initiatives and recent product approvals, particularly in the competitive biotech sector.

Strategic Developments Fueling Growth

Apotex's recent approval for SEVMIA™ positions the company to capitalize on the growing demand for chronic weight management solutions. This approval not only enhances its product portfolio but also strengthens its market presence, attracting investor interest and boosting stock performance.

Investor Sentiment and Future Outlook

The current upward trend in Apotex's stock reflects a broader optimism in the biotech sector. However, investors should remain vigilant regarding potential market fluctuations and the company's ability to navigate regulatory challenges as it continues to expand its offerings.


Wealth Awesome
Written by

Wealth Awesome

Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.

View Full Profile →

✅ Reviewed by Certified Financial Professionals

This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.

Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.

📊 Data AccuracyVerified sources
🇨🇦 Canadian FocusLocal expertise
🔍 Fact-CheckedEditorial review

⚠️ Professional Disclaimer

This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.

Published: July 7, 2026
Last Updated: October 21, 2026

Core portfolio

Awesome Portfolio™

14.8% a year since 2017, against 9.7% for the S&P/TSX Composite. Ten stocks, easy to manage. We update it once a month.

Annualized

+14.8%

Awesome Portfolio™

+9.7%

S&P/TSX

+5.0 pp better a year

Total return

+254%

Awesome Portfolio™

+134%

S&P/TSX

+119 pp better than the TSX

2017-07-31 to 2026-09-29, dividends reinvested, before fees and tax.

Awesome Portfolio™S&P/TSX CompositeCumulative return · 2017-07-31–2026-09-29
-11.7%42.5%96.7%150.9%205.1%259.3%Jul 17Oct 19Feb 22Jun 24Sep 26